Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xtant Medical HoldingsFRA:XMS +1.10%27 Debt-to-Equity is 0.32 as of Mar. 2026, which is 37% below its 10-year median of 0.51. GuruFocus rates FRA:XMS with a GF Score™ of 27/100 and a GF Value™ of €0.52. The stock has 4 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Xtant Medical Holdings ranks worse than 59.07% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Xtant Medical Holdings's Debt-to-Equity or its related term are showing as below:
FRA:XMS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -245.75 Med: 0.51 Max: 7.8
Current: 0.32
During the past 13 years, the highest Debt-to-Equity Ratio of Xtant Medical Holdings was 7.80. The lowest was -245.75. And the median was 0.51.
FRA:XMS's Debt-to-Equity is ranked worse than 59.07% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:XMS: 0.32
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Xtant Medical Holdings Debt-to-Equity Related Terms
Xtant Medical Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Xtant Medical Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:XMS vs NNOX, POSC, MDAI: Debt-to-Equity Comparison
For the Medical Devices subindustry, Xtant Medical Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xtant Medical Holdings Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Xtant Medical Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xtant Medical Holdings (FRA:XMS) has a Debt-to-Equity of 0.32 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xtant Medical Holdings and its competitors. This is 37% below median its historical median of 0.51. According to the industry distribution chart, Xtant Medical Holdings ranks #417 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 59.1%.
Is Xtant Medical Holdings' Debt-to-Equity too high?
Xtant Medical Holdings' current Debt-to-Equity of 0.32 is 37% below median its 10-year median of 0.51. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Xtant Medical Holdings' value of 0.32 is 39.1% above this industry median. Based on the distribution chart, Xtant Medical Holdings ranks #417 out of 706 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xtant Medical Holdings has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Debt-to-Equity compare to NNOX and POSC?
According to the Medical Devices & Instruments industry distribution chart, Xtant Medical Holdings ranks #417 out of 706 companies for Debt-to-Equity. This places Xtant Medical Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Xtant Medical Holdings' value of 0.32 is 39.1% above this benchmark. While the company's 10-year median is 0.51 vs. the industry median of 0.23, Xtant Medical Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xtant Medical Holdings's current Debt-to-Equity of 0.32 is 39.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xtant Medical Holdings and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xtant Medical Holdings's current Debt-to-Equity is 0.32, which is 37% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Xtant Medical Holdings (FRA:XMS) has a current Debt-to-Equity of 0.32. The stock's GF Value™ is €0.52, compared to a current price of €0.37 — trading 29.2% below its estimated fair value. The current Debt-to-Equity is 0.32, which is 37% below median its 10-year median of 0.51 and 39.1% above the Medical Devices & Instruments industry median of 0.23. Xtant Medical Holdings' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Xtant Medical Holdings (FRA:XMS), the current Debt-to-Equity is 0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xtant Medical Holdings (FRA:XMS) Overvalued in 2026?
Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued.
The current stock price of €0.37 is trading 29.2% below its estimated GF Value™ of €0.52.
Key valuation signals for FRA:XMS:
Debt-to-Equity: 0.32 (37% below median its 10-year median of 0.51)
GF Value™: €0.52 vs. price of €0.37 (29.2% below fair value)
Industry Position: 39.1% above the Medical Devices & Instruments median (#417 of 706)
No single metric tells the full story. See the FRA:XMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
27GF Score
Get the complete analysis for FRA:XMS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XMS has been successfully added to your 
